



Spyre Therapeutics, Inc. (f/k/a Aeglea BioTherapeutics, Inc.)  
CVR Payment Statement for Quarter Ending June 30, 2025

<u>Line Item</u>	<u>Calculation Ref</u>	<u>Payments to Date</u> <u>Amount</u>	<u>August 2025</u> <u>Amount</u>
Gross Proceeds	<b>A</b>	\$ 16,839,970.00	\$ 7,000,000.00
Permitted Deductions	<b>B</b>	(6,407,492.49)	(135,754.53)
Net Proceeds	<b>C = A + B</b>	10,432,477.51	6,864,245.47
Adjustment Amount	<b>D</b>	(1,000,000.00)	-
<b>CVR Cash Payment</b>	<b>E = C + D</b>	<b>9,432,477.51</b>	<b>6,864,245.47</b>
Holdback, per CVR Payment definition	<b>F = E x 15%</b>	(1,414,871.63)	(1,029,636.82)
<b>CVR Payment</b>	<b>G = E + F</b>	<b>8,017,605.88</b>	<b>5,834,608.65</b>
<b>90% per Section 2.4</b>	<b>H = G x 90%</b>	<b>7,215,845.30</b>	<b>5,251,147.78</b>
<b>Number of Outstanding CVRs</b>		<b>94,280,501</b>	<b>94,280,501</b>
<b>CVR Payment per Outstanding CVR</b>		<b>\$ 0.076536</b>	<b>\$ 0.055697</b>